melanoma

[Molecular Therapy Oncolytics] Non-viral/plasmid-based programmed cell death protein 1 (PD-1) knockout was carried out immediately prior to the traditional 14-day tumor-infiltrating lymphocytes-based ACT rapid expansion protocol.

[Clinical & Translational Immunology] Investigators analyzed the frequency and functional profile of circulating and tumor-infiltrating mucosal-associated invariant T cells in human melanoma patients. Using flow cytometry, they compared these across metastatic sites and between ICI responders vs. non-responders as well as healthy donors.

[Rubius Therapeutics, Inc.] Rubius Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelia carcinoma and triple-negative breast cancer.

[Cell Reports] Scientists found that Tfap2b and a select set of target genes specified an melanocyte stem cell population at the dorsal root ganglia in zebrafish.

[Nature Communications] Prediction identified genes and pathways known to be associated with anti-PD1, and was further validated by six CRISPR gene sets associated with tumor resistance to cytotoxic T cells and targets of the 36 compounds that had been tested in clinical trials for combination treatments with anti-PD1.

[Bioorganic Chemistry] Caffeine has been studied as a potentiating agent in chemotherapy against some types of cancer, but there are few reports on its effects on melanoma. Scientists investigated caffeine's ability to enhance the effects of dacarbazine in vitro.